Eudaimonia Partners’s Cytosorbents Corp CTSO Stock Holding History

Eudaimonia Partners’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-23,500	Closed	-$44.2K	–	271
2023 Q3	$44.2K	Hold	23,500	–	–	0.01%	322
2023 Q2	$84.4K	Buy	23,500 +3,500	+18%	+$11.1K	0.02%	341
2023 Q1	$67.4K	Hold	20,000	–	–	0.02%	343
2022 Q4	$31K	Buy	20,000 +9,000	+82%	+$13.4K	0.01%	341
2022 Q3	$15K	Hold	11,000	–	–	﹤0.01%	338
2022 Q2	$24K	Buy	+11,000	New	+$25.3K	﹤0.01%	383
2021 Q2	–	Sell	-4,000	Closed	-$35K	–	574
2021 Q1	$35K	Sell	4,000 -3,000	-43%	-$28.6K	0.01%	752
2020 Q4	$56K	Hold	7,000	–	–	0.01%	578
2020 Q3	$56K	Hold	7,000	–	–	0.01%	533
2020 Q2	$69K	Hold	7,000	–	–	0.03%	424
2020 Q1	$54K	Buy	+7,000	New	+$35.3K	0.02%	444

Other funds holding CTSO

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Eudaimonia Partners's CTSO Position: Q4 2023 in Review

Eudaimonia Partners sold out of Cytosorbents Corp (CTSO) in Q4 2023, closing a stake of 23,500 shares — an estimated $44.2K sold.

Eudaimonia Partners first reported a position in CTSO in Q1 2020 and held it in 11 quarters. The position peaked at $84.4K in Q2 2023. 54 funds tracked by Wall St. Rank hold CTSO as of Q4 2023.

Eudaimonia Partners reported no remaining Cytosorbents Corp position as of Q4 2023 after selling out during the quarter.
Eudaimonia Partners sold 23,500 Cytosorbents Corp shares in Q4 2023, an estimated $44.2K.
Eudaimonia Partners first reported a position in Cytosorbents Corp in Q1 2020 and held it in 11 quarters.
Eudaimonia Partners's Cytosorbents Corp position peaked at $84.4K in Q2 2023.
54 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q4 2023.

Based on Eudaimonia Partners's 13F filing for Q4 2023, filed 8 Feb 2024.